$ZVRA News

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zevra Therapeutics to Present at Upcoming Investor Conferences

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual Symposium

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics

Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Says Expects To Continue Engagement With The U.S. FDA In The H2 2026 To Explore Pathways To Accelerate Clinical Development

UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M Estimate